

Resource Summary Report

Generated by RRID on Jul 30, 2026

PE/Cyanine5 anti-human CD3

RRID:AB_314046

Type: Antibody

Proper Citation

BioLegend Cat# 300310, RRID:AB_314046

Antibody Information

URL: http://antibodyregistry.org/AB_314046

Proper Citation: BioLegend Cat# 300310, RRID:AB_314046

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine5 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_314046

Vendor: BioLegend

Catalog Number: 300310

Alternative Catalog Numbers: 300309

Record Creation Time: 20250820T041720+0000

Record Last Update: 20250820T183401+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine5 anti-human CD3.

No alerts have been found for PE/Cyanine5 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wagoner ZW, et al. (2025) Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines. *Cell stem cell*, 32(4), 529.

Jakobsen NA, et al. (2025) Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq. *STAR protocols*, 6(2), 103832.

Jakobsen NA, et al. (2024) Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. *Cell stem cell*, 31(8), 1127.

Kastenschmidt JM, et al. (2024) A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment. *Cell stem cell*, 31(3), 410.

Turkalj S, et al. (2023) GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells. *Cell stem cell*, 30(5), 722.

Hartana CA, et al. (2023) IL-15-dependent immune crosstalk between natural killer cells and dendritic cells in HIV-1 elite controllers. *Cell reports*, 42(12), 113530.

Liu H, et al. (2023) Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. *Cancer cell*, 41(4), 693.

Laforêts F, et al. (2023) Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. *iScience*, 26(4), 106514.

Turkalj S, et al. (2023) A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells. *STAR protocols*, 4(4), 102641.

Nahi H, et al. (2022) Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. *Cell reports. Medicine*, 3(2), 100508.

Zaitsev A, et al. (2022) Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. *Cancer cell*, 40(8), 879.

Gupta R, et al. (2020) Nov/CCN3 Enhances Cord Blood Engraftment by Rapidly Recruiting Latent Human Stem Cell Activity. *Cell stem cell*, 26(4), 527.

Rodriguez-Meira A, et al. (2019) Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing. *Molecular cell*, 73(6), 1292.

Labuhn M, et al. (2019) Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. *Cancer cell*, 36(2), 123.

Böiers C, et al. (2018) A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1. *Developmental cell*, 44(3), 362.